howestreetbull
5年前
VXL.v $VXLLF Vaxil Announces Progress on Research and Development Activities
by @nasdaq on 29 Sep 2021, 04:50
Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces here on the progress of its various research and development activities including; development of oral formulation for signal peptides ("SPs"), research on the utilization of P-Esbp polymer as a novel anti-cancer drug, and the issuance of U.S. patent No. 11135277 on 5 October, 2021, titled: “Antigen specific multi epitope-based anti-infective vaccines”.
Vaxil is continuing with its mission to bring novel medicines to the public, which includes the utilization of SPs as anti-cancer and anti-microbial vaccines. In order to improve treatment procedures of SP-based vaccines, Vaxil has engaged in efforts to develop a SP-based oral formulation. Vaxil believes that oral delivery of SPs can benefit patients by simplifying administration procedures without compromising the therapeutic efficacy, and it may also simplify manufacturing processes, transportation, and storage conditions.
SP-based oral formulation is being developed independently, as well as in partnership with an established oral delivery company. So far, various potential oral formulations were explored for their ability to solubilize SPs and for their feasibility to be used in in vivo studies against MUC1 and COVID-19 targets. A potentially promising formulation was identified and currently it is being further studied to better define its performance. In parallel, an in vivo study was initiated aimed at testing the ability of the SP-based oral formulation to induce a systemic immune response in mice.
As previously reported Vaxil is making progress in the licensed drug delivery polymer that targets with high affinity E-selectin (P-Esbp), which was invented by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev. E-selectin is an important component in inflammation, metastasis, and tumor growth processes, and Prof. Ayelet David’s previous work demonstrated therapeutic efficacy of P-Esbp conjugated with the anti-cancer drug doxorubicin (P-Esbp-DOX) in prolonging the survival of tumor-bearing mice with both primary (Lewis lung carcinoma) and metastatic tumors (melanoma lung metastasis model).
In order to further explore and establish the potential of P-Esbp-DOX for treating cancer, an in vivo experiment was designed aimed at evaluating the therapeutic efficacy of P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal tumors. To this end, P-Esbp was successfully conjugated with DOX, and the maximum tolerated dose of P-Esbp-DOX was determined in the suitable mouse strain. Currently the in vivo treatment study is ongoing, and the results would help Vaxil to strategize the appropriate approach for a clinical program.
In addition, Vaxil announces that it further strengthens its intellectual property assets regarding the treatment of tuberculosis by using SPs, since a patent will be issued in the U.S. (U.S. patent No. 11135277) on 5 October, 2021, titled: “Antigen specific multi epitope-based anti-infective vaccines”, that includes claims relating to various SP-based anti-tuberculosis vaccines.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The Company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early-stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
CONTACT INFORMATION
For further information please visit https://vaxil-bio.com/ or contact:
Gadi Levin, CFO — info@vaxil-bio.com, 647-558-5564
Primary Logo
howestreetbull
5年前
VXL.v $VXLLF Vaxil Provides Strategy Update From Conclusion of COVID-19 Challenge Study
by @nasdaq on 17 Feb 2021, 10:25
Not for distribution by US newswire or in United States
NESS-ZIONA, ISRAEL, Feb. 17, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, today reports results of the previously disclosed COVID-19 vaccine candidate challenge experiment and the strategy going forward.
Vaxil established the USAMRIID collaboration (CRADA) based on the global need for a viable COVID-19 vaccine utilizing an alternative technology that demonstrates cellular and humoral responses, both of which are necessary. In this rapidly moving pandemic, variants have become the established infection model, which can be better addressed with Vaxil’s SP approach. Neutralizing antibody technologies may require frequent modifications while Vaxil’s signal peptide (“SP”) technology may provide long-term efficacy as the virus mutates.
The USAMRIID COVID-19 mouse model challenge experiment demonstrated that Vaxil’s SP-based vaccine candidate generated a specific immune response. This was not, however, accompanied by vaccine protection of the animals.
The Company plans to conduct additional analyses and on the basis of the understanding obtained, refine aspects of experiment design, including dosing levels and regimens, and alternate animal models that may allow future investigation of the unique and specific aspects of SP’s as immunogens. In addition, the Company will evaluate alternate peptide delivery approaches, including oral administration. This strategy focuses future efforts on the unique benefits of SP’s to sustain Vaxil’s competitive advantage over the longer term, beyond the current crisis environment, when it can realistically achieve approval for human use.
The Company’s strategy to deliver value over the long-term is based on potentially unique benefits of SPs including their broad and strong immune response, both cellular and humoral, their reduced propensity to genetic mutation and the advantage of efficient manufacturing.
“We were pleased to see the encouraging immune response and are excited to pursue further testing to highlight the unique advantages of SPs as a technology, though we had hoped to be able to demonstrate higher levels of protection in our first challenge experiment. It’s not uncommon to see such results at this early stage. We will work diligently with our international team of experts to further understand the data as COVID-19 is unfortunately going to be around for a long time. Whilst we had hoped to get into the clinic sooner, we believe that our technology could still be very relevant in the fight against COVID-19 and other infectious diseases,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “thanks to our relatively strong balance sheet, we have sufficient funds to continue the pre-clinical development of our potential vaccine and our other research programs.”
Dr. Michael Berelowitz, Vaxil’s newly appointed senior advisor the board of directors added: “Vaxil’s innovative approach in targeting the SP domain of clinically meaningful cancer and infectious disease molecules provided the stimulus for joining the company. The demonstration in this study of COVID-19 SP immunogenicity provides support and impetus for the concept. These results, together with those previously seen in multiple myeloma and tuberculosis, provide support for the Vaxil strategy moving forward and their investigative approach toward developing critical new therapeutics.”
The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
ABOUT VAXIL
The company posts periodic updates through videos from the official company’s youtube channel https://www.youtube.com/channel/UC0M029aN8g6beW09Drgt0dQ
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
About the U.S. Army Medical Research Institute of Infectious Diseases
For over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions - vaccines, drugs, diagnostics, information, and training programs - that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit http://www.usamriid.army.mil.
[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]
CONTACT INFORMATION
For further information please visit http://vaxil-bio.com/ or contact:
North Equities, info@northequities.com
David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Company Youtube channel
Primary Logo
howestreetbull
5年前
by @nasdaq on 29 Dec 2020, 13:10
VAXIL Provides Update on USAMRIID and Oral Experiments
NESS-ZIONA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that further to our press release dated December 3, 2020, in respect to our cooperative research and development agreement (CRADA) with US Army Medical Research Institute of Infectious Diseases (“USAMRIID”), the mice have received two of the three scheduled vaccinations. The third and final vaccine is scheduled to be administered later this week. USAMRIID reports that the mice appear to be fine having responded normally to the injections administered to date and that the experiment is proceeding on schedule. The Company expects that the mice will be “challenged” with the COVID-19 virus in mid-January 2021, after having had the chance to develop an immune response. Vaxil expects to provide a further update at the beginning of February 2021.
In addition, The Company reported that it initiated an exploratory pre-clinical study to determine the viability of oral administration. This experiment remains on schedule, having completed the first three doses successfully. Vaxil anticipates reporting results in late January 2021.
The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
Recently completed non-brokered private placement
The Company wishes to further update that certain officers and/or directors of the Company (the “Related Parties”) participated in the private placement (see press release dated December 10, 2020), which participation constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). Such Related Party transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to the related parties nor the consideration being paid by the Related Parties exceeded 25% of the Company’s market capitalization.
All finders were arm’s length to the Company.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
About the U.S. Army Medical Research Institute of Infectious Diseases
For over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions - vaccines, drugs, diagnostics, information, and training programs - that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit http://www.usamriid.army.mil.
[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]
CONTACT INFORMATION
For further information please visit http://vaxil-bio.com/ or contact:
David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Primary Logo
howestreetbull
6年前
by @nasdaq on 3 Dec 2020, 04:55
Vaxil Provides Business Update on Corvax™ Experiments
Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that further to our press release dated October 26, 2020, in respect to our cooperative research and development agreement (CRADA) with US Army Medical Research Institute of Infectious Diseases (“USAMRIID”), we have completed the manufacturing of our Corvax™ product for this research project, which is expected to arrive at USAMRIID by the end of this week. We anticipate the first Corvax™ injections in mice will be administered during the week of December 14, 2020.
The Company further notes that it has initiated an exploratory pre-clinical study to determine the viability of administering Corvax™ orally. Results from this work are anticipated in January 2021.
Both the above experiments are being financed from existing working capital.
The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
About the U.S. Army Medical Research Institute of Infectious Diseases
For over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions - vaccines, drugs, diagnostics, information, and training programs - that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit http://www.usamriid.army.mil.
[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]
CONTACT INFORMATION
For further information please visit http://vaxil-bio.com/ or contact:
David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Primary Logo
howestreetbull
6年前
VXL.v $VXLLF Vaxil Enters Into a Cooperative Research and Development Agreement With U.S. Army Medical Research Institute of Infectious Diseases (“USAMRIID”)
by @nasdaq on 26 Oct 2020, 08:57
NOT FOR DISTRIBUTION BY US NEWSWIRE OR IN UNITED STATES
NESS-ZIONA, Israel, Oct. 26, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that on October 26, 2020, it has entered into a cooperative research and development agreement (CRADA) with USAMRIID under which USAMRIID will test CorVax™ for its ability to specifically prevent COVID-19 in mice.
Vaxil recently reported that its CorVax™ successfully generated an immune response in the experiment carried out at the Allergy and Clinical Immunology Unit at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel by Dr. David Hagin. As a result, the Company is progressing to the next study to test whether this immune response is specific enough to COVID-19 to provide protection against the virus in a mouse model.
As scientists and companies race to find vaccines to prevent COVID-19 infection, some platforms are focused on mRNA, others on viral vectors, viruses and various subunits. Vaxil is, to the best of the Company’s knowledge, the only company working with signal peptides, which offer unique advantages of efficacy in stimulating a broad immune response while achieving a suitable safety profile. Vaxil’s signal peptide platform has proven safety in a phase 1/2a study in oncology.
“The initial immunogenicity data sound intriguing,” said Dr. Joseph W. Golden, a principal investigator in USAMRIID’s virology division. “We look forward to evaluating this vaccine formulation for its potential to protect against SARS-CoV-2 in our mouse models.”
The work to be performed by USAMRIID will be financed out of the Company’s existing working capital, according to David Goren, Vaxil’s Chairman and Chief Executive Officer. The team hopes to secure additional funding for future studies.
“We are pleased to have USAMRIID assess our potential COVID-19 vaccine,” said Goren. “The work in the US will support and strengthen the experiments we have already done in Israel in our in-vivo study. Together, the combined research will help the Company plan and execute more efficient pre-clinical and clinical programs.”
The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
About the U.S. Army Medical Research Institute of Infectious Diseases
For over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions - vaccines, drugs, diagnostics, information, and training programs - that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit http://www.usamriid.army.mil.
[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]
CONTACT INFORMATION
For further information please visit http://vaxil-bio.com/ or contact:
David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Primary Logo
howestreetbull
6年前
VXL.v $VXLLF Vaxil Provides Update on In Vivo Study
by @nasdaq on 27 Aug 2020, 07:52
Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, would like to provide an update on the following:
On July 20, 2020, the Company announced the commencement of the in vivo (animal) study for Vaxil’s COVID-19 vaccine candidate (Corvax™), under the guidance of Dr. Hagin, Director of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical Center. The experiment was designed to evaluate the immune response to Vaxil’s Corvax™ and was commenced with the first animal injection administered on July 14, 2020.
Over the last few weeks, Corvax™ injections were administered and are now complete. The Company is now proceeding to evaluate the results and expects to complete this process including analyses during the next four to six weeks, at which time it will announce results and next steps.
“We are acutely aware that the market in general, and our shareholders specifically, are anticipating our progress, and would like more frequent updates, however, the nature of the science is such that experiments take time and cannot be accelerated,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “we will continue to apply best practice in our science and update shareholders when we have credible and meaningful information to report.”
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
CONTACT INFORMATION
For further information please visit http://vaxil-bio.com/ or contact:
David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Primary Logo
howestreetbull
6年前
Shorts continue to cover their positions...
cheers,
hsb
Symbol » Issue Name » Shares » Net Change » Date
$VXL.V » VAXIL BIO LTD. » 140,235 » -62,166 » 18 Jun 2020
$VXL.V » VAXIL BIO LTD. » 202,401 » 8,068 » 4 Jun 2020
$VXL.V » VAXIL BIO LTD. » 194,333 » -354,651 » 21 May 2020
$VXL.V » VAXIL BIO LTD. » 548,984 » -586,915 » 5 May 2020
$VXL.V » VAXIL BIO LTD. » 1,135,899 » -724,060 » 20 Apr 2020
$VXL.V » VAXIL BIO LTD. » 1,135,899 » -724,060 » 20 Apr 2020
$VXL.V » VAXIL BIO LTD. » 1,859,959 » -446,064 » 5 Apr 2020
$VXL.V » VAXIL BIO LTD. » 2,306,023 » 1,040,913 » 19 Mar 2020
$VXL.V » VAXIL BIO LTD. » 1,265,110 » 1,194,339 » 5 Mar 2020
Gumby007
6年前
Magnifier Research has offered a new research report titled Global Dendritic Cell Cancer Vaccines Market Size, Status and Forecast 2019-2025 Report just released mentions vxl “ The report speaks about the summary of the market competitive spectrum: 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck, Northwest Biotherapeutics, Glaxo Smith Kline, Tellaorporation, Vaxil BioTherapeutics,” https://nysenewstimes.com/global-dendritic-cell-cancer-vaccines-market-growth-analysis-2019-2025-3m-company-activarti-argos-therapeutics/
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
delerious1
2年前
superstockpicker
6年前
FooBarAndGrill
6年前
メールアドレスで登録
